BioNTech SE

158.59-2.33-1.45%Vol 650.37K1Y Perf -55.20%
Aug 11th, 2022 16:00 DELAYED
BID158.31 ASK163.77
Open161.32 Previous Close160.92
Pre-Market- After-Market159.11
 - -  0.52 0.33%
Target Price
240.70 
Analyst Rating
Moderate Buy 2.20
Potential %
51.78 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     64.58
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★★     85.44
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
★★★★+     56.55
Price Range Ratio 52W %
11.97 
Earnings Rating
Market Cap38.49B 
Earnings Date
8th Aug 2022
Alpha0.11 Standard Deviation0.29
Beta-0.09 

Today's Price Range

158.48165.83

52W Range

117.08464.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-13.39%
1 Month
-1.75%
3 Months
0.37%
6 Months
-7.23%
1 Year
-55.20%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BNTX158.59-2.3300-1.45
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
78.60
79.10
79.50
-57.40
56.00
RevenueValueIndustryS&P 500US Markets
19.92B
81.97
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 20227.697.31-4.94
Q01 20229.1415.9874.84
Q04 20218.0213.9373.69
Q03 202111.7914.5623.49
Q02 20218.3512.9855.45
Q01 20214.315.2922.74
Q04 2020-0.571.87428.07
Q03 2020-0.46-1.03-123.91
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report7.69
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume650.37K
Shares Outstanding242.69K
Shares Float243.02M
Trades Count15.73K
Dollar Volume105.20M
Avg. Volume1.33M
Avg. Weekly Volume1.83M
Avg. Monthly Volume1.00M
Avg. Quarterly Volume1.15M

BioNTech SE (NASDAQ: BNTX) stock closed at 158.59 per share at the end of the most recent trading day (a -1.45% change compared to the prior day closing price) with a volume of 650.37K shares and market capitalization of 38.49B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1310 people. BioNTech SE CEO is Ugur Sahin.

The one-year performance of BioNTech SE stock is -55.2%, while year-to-date (YTD) performance is -38.48%. BNTX stock has a five-year performance of %. Its 52-week range is between 117.08 and 464, which gives BNTX stock a 52-week price range ratio of 11.97%

BioNTech SE currently has a PE ratio of 2.90, a price-to-book (PB) ratio of 2.55, a price-to-sale (PS) ratio of 1.96, a price to cashflow ratio of 8.30, a PEG ratio of 2.32, a ROA of 104.99%, a ROC of 136.38% and a ROE of 139.59%. The company’s profit margin is 56.00%, its EBITDA margin is 79.50%, and its revenue ttm is $19.92 Billion , which makes it $81.97 revenue per share.

Of the last four earnings reports from BioNTech SE, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $7.69 for the next earnings report. BioNTech SE’s next earnings report date is -.

The consensus rating of Wall Street analysts for BioNTech SE is Moderate Buy (2.2), with a target price of $240.7, which is +51.78% compared to the current price. The earnings rating for BioNTech SE stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioNTech SE has a dividend yield of 0.00% with a dividend per share of $0.00 and a payout ratio of -%.

BioNTech SE has a Sell technical analysis rating based on Technical Indicators (ADX : 13.87, ATR14 : 8.71, CCI20 : -53.86, Chaikin Money Flow : 0.26, MACD : 2.43, Money Flow Index : 47.31, ROC : -0.71, RSI : 38.93, STOCH (14,3) : 15.12, STOCH RSI : 0.10, UO : 51.14, Williams %R : -84.88), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioNTech SE in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (40.00 %)
3 (30.00 %)
2 (25.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
6 (60.00 %)
7 (70.00 %)
6 (75.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.20
Moderate Buy
2.40
Moderate Buy
2.50

BioNTech SE

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.

CEO: Ugur Sahin

Telephone: +49 613190840

Address: An der Goldgrube 12, Mainz D-55131, , DE

Number of employees: 1 310

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

57%43%

Bearish Bullish

58%42%

TipRanks News for BNTX

Fri, 15 Jul 2022 16:48 GMT BioNTech SE (BNTX) Gets a Hold Rating from Morgan Stanley

- TipRanks. All rights reserved.

Mon, 11 Jul 2022 10:16 GMT BioNTech SE (BNTX) Gets a Buy Rating from H.C. Wainwright

- TipRanks. All rights reserved.

Wed, 06 Jul 2022 10:25 GMT Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Ayala Pharmaceuticals (AYLA)

- TipRanks. All rights reserved.

Thu, 30 Jun 2022 10:16 GMT BioNTech SE (BNTX) Receives a Hold from UBS

- TipRanks. All rights reserved.

Mon, 27 Jun 2022 15:21 GMT BioNTech Gains on COVID-19 News, but is There More Afoot

- TipRanks. All rights reserved.

Mon, 27 Jun 2022 10:05 GMT BioNTech SE (BNTX) Receives a Buy from Berenberg Bank

- TipRanks. All rights reserved.

Tue, 24 May 2022 12:47 GMT BioNTech SE (BNTX) Gets a Hold Rating from Goldman Sachs

- TipRanks. All rights reserved.

Mon, 09 May 2022 21:15 GMT BioNTech SE (BNTX) Gets a Hold Rating from J.P. Morgan

- TipRanks. All rights reserved.

Mon, 09 May 2022 13:55 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX) and Relay Therapeutics (RLAY)

- TipRanks. All rights reserved.

Thu, 31 Mar 2022 09:55 GMT BioNTech SE (BNTX) Receives a Hold from J.P. Morgan

- TipRanks. All rights reserved.

Wed, 30 Mar 2022 13:53 GMT BioNTechs Q4 Earnings Impress Investors

- TipRanks. All rights reserved.

Fri, 18 Mar 2022 13:55 GMT BioNTech SE (BNTX) Receives a Hold from Jefferies

- TipRanks. All rights reserved.

Wed, 02 Mar 2022 09:11 GMT Understanding Pfizers Newly Added Risk Factors

- TipRanks. All rights reserved.

Mon, 07 Feb 2022 11:25 GMT Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX) and Genmab (GMAB)

- TipRanks. All rights reserved.

Wed, 12 Jan 2022 14:45 GMT BioNTech SE (BNTX) Receives a Hold from Goldman Sachs

- TipRanks. All rights reserved.

Tue, 04 Jan 2022 11:15 GMT Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Zynex (ZYXI) and Edesa Biotech (EDSA)

- TipRanks. All rights reserved.

News

Stocktwits